FDA Deputy Commissioner Considered for Acting Commissioner Role
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 21 hours ago
0mins
Source: seekingalpha
- Acting Commissioner Candidates: FDA Deputy Commissioner Kyle Diamantas is being considered for the acting commissioner role as current Commissioner Marty Makary's tenure is reportedly ending soon, which could impact the agency's policy direction and operational efficiency.
- Additional Candidates: Alongside Diamantas, Deputy Commissioner for Policy, Legislation, and International Affairs Grace Graham and senior counselor to HHS Secretary Robert F. Kennedy Jr., Sara Brenner, are also in the running, indicating a diverse consideration for FDA leadership.
- Former Commissioners Considered: Former FDA Commissioner Stephen Hahn and former acting commissioner and Assistant Health Secretary Brett Giroir are being considered for a permanent role, suggesting a potential return to a more traditional leadership style at the FDA.
- Industry Implications: Changes in FDA leadership may affect pharmaceutical companies like Pfizer, particularly in terms of policy formulation and regulatory enforcement, which could influence drug approvals and market strategies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 26.480
Low
24.00
Averages
28.56
High
35.00
Current: 26.480
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer's Stock Drops 50% Yet Remains Attractive for Investors
- Significant Stock Decline: Pfizer's stock has plummeted over 50% since its 2021 peak, primarily due to unmet expectations for COVID vaccine revenues, which has intensified market pessimism regarding its future prospects.
- High Dividend Appeal: Despite facing challenges, Pfizer currently offers a 6.5% dividend yield, providing a stable income source for long-term investors while also laying the groundwork for potential capital appreciation in the future.
- Drug Development Dynamics: Although Pfizer has fallen behind in the GLP-1 weight-loss drug race, it quickly pivoted by acquiring a company with a more promising drug candidate, demonstrating its agility in drug development and potential for future product launches.
- Management Confidence: Pfizer's management has clearly stated its intention to maintain the current dividend level despite pressures on profitability, indicating a commitment to shareholder returns while working to restore growth.
See More
Pfizer Faces Challenges Yet Remains a Worthy Investment
- Patent Expiration Risk: Pfizer faces significant revenue declines as several blockbuster drugs near patent expiration, leading to a pessimistic market outlook reflected in a stock price drop of over 50% from 2021 highs, indicating investor overreaction to its future prospects.
- Competitive Pressure: Although Pfizer has fallen behind in the GLP-1 weight-loss drug race, it quickly pivoted by acquiring a promising drug candidate, demonstrating its ongoing competitiveness in this market segment.
- Dividend Commitment: Management has committed to maintaining the current dividend level, and since dividends are paid from cash flow rather than earnings, the company can sustain these payments for a while as it aims to return to earnings growth, appealing to aggressive income investors.
- Investment Return Potential: With the stock's sharp decline, investors can enter at a 6.5% dividend yield, which, combined with the potential success of Pfizer's drug pipeline, could yield both robust income and capital appreciation, presenting a compelling investment opportunity.
See More
S&P 500 Earnings Accelerate with Strong Performance
- Strong Earnings Performance: This week, over 125 S&P 500 companies reported earnings, with 110 exceeding EPS expectations and 103 showing year-over-year earnings growth, indicating resilience in corporate profitability amid changing economic conditions.
- AMD Leads Tech Sector: Advanced Micro Devices (AMD) reported robust revenue of $10.3 billion and an adjusted EPS of $1.37, driven by a 57% surge in Data Center sales, with a Q2 revenue outlook of $11.2 billion, highlighting strong demand in AI and data processing.
- Disney's Continued Growth: Disney (DIS) reported $25.17 billion in revenue and raised its annual EPS growth target to 12%, reflecting its sustained competitiveness and market demand in the entertainment and media sector.
- Super Micro's Optimistic Outlook: Super Micro Computer (SMCI) reported a challenging start with $10.2 billion in revenue, missing expectations, but significantly raised its 2026 revenue guidance to between $38.9 billion and $40.4 billion, indicating strong anticipated demand for AI computing infrastructure.
See More
Trump Denies Plans to Oust FDA Commissioner Makary
- Trump's Denial: Trump stated late Friday that he is unaware of any proposal to oust FDA Commissioner Marty Makary, despite multiple reports suggesting increasing pressure from senior White House officials for his departure, indicating potential internal conflicts.
- FDA Leadership Turmoil: Since Makary's nomination in November 2024, the FDA has seen several high-profile departures, including Richard Pazdur, the director of the Center for Drug Evaluation and Research, and Vinay Prasad, former head of the Center for Biologics Evaluation and Research, highlighting instability within the agency.
- Impact of Media Reports: The Wall Street Journal's initial report on Trump's plans to dismiss Makary contrasts with Trump's claims of ignorance, which may undermine public trust in FDA leadership and the agency's credibility.
- Future Challenges: Given the backdrop of leadership turnover and external pressures, Makary's ability to lead will be increasingly scrutinized, particularly in drug regulation and public health policy, potentially affecting the FDA's decision-making efficiency and public health safety.
See More
Top Healthcare Stocks for Retirees
- Pfizer's Challenges and Opportunities: As an industry-leading pharmaceutical company, Pfizer faces challenges from multiple patent expirations, yet offers a high dividend yield of 6.5%; however, with a payout ratio exceeding 100%, it may be more suitable for aggressive investors.
- Medtronic's Transformation Journey: Medtronic boasts a 48-year streak of annual dividend increases with a current yield of 3.6%, as the company is restructuring by cutting costs and focusing on profitable divisions, which is expected to restore growth and enhance market valuation.
- Omega's Stable Returns: Omega Healthcare Investors focuses on senior housing properties and, despite facing difficulties during the pandemic, has maintained its dividend; with a current yield of 5.8%, the company is gradually recovering and is ideal for investors seeking stable income.
- Retiree Investment Choices: For retirees, Pfizer, Medtronic, and Omega Healthcare represent compelling high-yield healthcare stocks to consider, each offering distinct business models that can provide stable cash flow and potential long-term growth for investment portfolios.
See More
Investment Opportunities in Healthcare Stocks
- Pfizer's Challenges and Opportunities: As an industry-leading pharmaceutical company, Pfizer faces challenges from multiple patent expirations; however, with a current dividend yield of 6.5% and a payout ratio exceeding 100%, it is more suited for aggressive investors, while the company remains committed to long-term growth.
- Medtronic's Transformation Journey: Medtronic boasts a 48-year history of annual dividend increases, currently offering a 3.6% yield, as the company is restructuring by cutting costs and focusing on its most profitable divisions, with expectations to return to growth and achieve higher market valuations post-transition.
- Omega Healthcare's Stable Returns: Omega Healthcare, focusing on senior housing properties, has a 5.8% dividend yield and, despite challenges during the pandemic, has begun to recover its business, positioning itself to benefit from the growing demand of an aging population in the long term.
- Choices for Retired Investors: For retirees, Pfizer, Medtronic, and Omega Healthcare represent high-yield healthcare stocks worth considering; although they operate under different business models, they all provide stable cash flow and potential for long-term growth in an investment portfolio.
See More
Pfizer's Stock Drops 50% Yet Remains Attractive for Investors
- Significant Stock Decline: Pfizer's stock has plummeted over 50% since its 2021 peak, primarily due to unmet expectations for COVID vaccine revenues, which has intensified market pessimism regarding its future prospects.
- High Dividend Appeal: Despite facing challenges, Pfizer currently offers a 6.5% dividend yield, providing a stable income source for long-term investors while also laying the groundwork for potential capital appreciation in the future.
- Drug Development Dynamics: Although Pfizer has fallen behind in the GLP-1 weight-loss drug race, it quickly pivoted by acquiring a company with a more promising drug candidate, demonstrating its agility in drug development and potential for future product launches.
- Management Confidence: Pfizer's management has clearly stated its intention to maintain the current dividend level despite pressures on profitability, indicating a commitment to shareholder returns while working to restore growth.
See More
Pfizer Faces Challenges Yet Remains a Worthy Investment
- Patent Expiration Risk: Pfizer faces significant revenue declines as several blockbuster drugs near patent expiration, leading to a pessimistic market outlook reflected in a stock price drop of over 50% from 2021 highs, indicating investor overreaction to its future prospects.
- Competitive Pressure: Although Pfizer has fallen behind in the GLP-1 weight-loss drug race, it quickly pivoted by acquiring a promising drug candidate, demonstrating its ongoing competitiveness in this market segment.
- Dividend Commitment: Management has committed to maintaining the current dividend level, and since dividends are paid from cash flow rather than earnings, the company can sustain these payments for a while as it aims to return to earnings growth, appealing to aggressive income investors.
- Investment Return Potential: With the stock's sharp decline, investors can enter at a 6.5% dividend yield, which, combined with the potential success of Pfizer's drug pipeline, could yield both robust income and capital appreciation, presenting a compelling investment opportunity.
See More
S&P 500 Earnings Accelerate with Strong Performance
- Strong Earnings Performance: This week, over 125 S&P 500 companies reported earnings, with 110 exceeding EPS expectations and 103 showing year-over-year earnings growth, indicating resilience in corporate profitability amid changing economic conditions.
- AMD Leads Tech Sector: Advanced Micro Devices (AMD) reported robust revenue of $10.3 billion and an adjusted EPS of $1.37, driven by a 57% surge in Data Center sales, with a Q2 revenue outlook of $11.2 billion, highlighting strong demand in AI and data processing.
- Disney's Continued Growth: Disney (DIS) reported $25.17 billion in revenue and raised its annual EPS growth target to 12%, reflecting its sustained competitiveness and market demand in the entertainment and media sector.
- Super Micro's Optimistic Outlook: Super Micro Computer (SMCI) reported a challenging start with $10.2 billion in revenue, missing expectations, but significantly raised its 2026 revenue guidance to between $38.9 billion and $40.4 billion, indicating strong anticipated demand for AI computing infrastructure.
See More
Trump Denies Plans to Oust FDA Commissioner Makary
- Trump's Denial: Trump stated late Friday that he is unaware of any proposal to oust FDA Commissioner Marty Makary, despite multiple reports suggesting increasing pressure from senior White House officials for his departure, indicating potential internal conflicts.
- FDA Leadership Turmoil: Since Makary's nomination in November 2024, the FDA has seen several high-profile departures, including Richard Pazdur, the director of the Center for Drug Evaluation and Research, and Vinay Prasad, former head of the Center for Biologics Evaluation and Research, highlighting instability within the agency.
- Impact of Media Reports: The Wall Street Journal's initial report on Trump's plans to dismiss Makary contrasts with Trump's claims of ignorance, which may undermine public trust in FDA leadership and the agency's credibility.
- Future Challenges: Given the backdrop of leadership turnover and external pressures, Makary's ability to lead will be increasingly scrutinized, particularly in drug regulation and public health policy, potentially affecting the FDA's decision-making efficiency and public health safety.
See More
Top Healthcare Stocks for Retirees
- Pfizer's Challenges and Opportunities: As an industry-leading pharmaceutical company, Pfizer faces challenges from multiple patent expirations, yet offers a high dividend yield of 6.5%; however, with a payout ratio exceeding 100%, it may be more suitable for aggressive investors.
- Medtronic's Transformation Journey: Medtronic boasts a 48-year streak of annual dividend increases with a current yield of 3.6%, as the company is restructuring by cutting costs and focusing on profitable divisions, which is expected to restore growth and enhance market valuation.
- Omega's Stable Returns: Omega Healthcare Investors focuses on senior housing properties and, despite facing difficulties during the pandemic, has maintained its dividend; with a current yield of 5.8%, the company is gradually recovering and is ideal for investors seeking stable income.
- Retiree Investment Choices: For retirees, Pfizer, Medtronic, and Omega Healthcare represent compelling high-yield healthcare stocks to consider, each offering distinct business models that can provide stable cash flow and potential long-term growth for investment portfolios.
See More
Investment Opportunities in Healthcare Stocks
- Pfizer's Challenges and Opportunities: As an industry-leading pharmaceutical company, Pfizer faces challenges from multiple patent expirations; however, with a current dividend yield of 6.5% and a payout ratio exceeding 100%, it is more suited for aggressive investors, while the company remains committed to long-term growth.
- Medtronic's Transformation Journey: Medtronic boasts a 48-year history of annual dividend increases, currently offering a 3.6% yield, as the company is restructuring by cutting costs and focusing on its most profitable divisions, with expectations to return to growth and achieve higher market valuations post-transition.
- Omega Healthcare's Stable Returns: Omega Healthcare, focusing on senior housing properties, has a 5.8% dividend yield and, despite challenges during the pandemic, has begun to recover its business, positioning itself to benefit from the growing demand of an aging population in the long term.
- Choices for Retired Investors: For retirees, Pfizer, Medtronic, and Omega Healthcare represent high-yield healthcare stocks worth considering; although they operate under different business models, they all provide stable cash flow and potential for long-term growth in an investment portfolio.
See More
